Lyra Therapeutics, Inc. (LYRA) Return on equity 2021–2024
Lyra Therapeutics, Inc. (LYRA) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-805.9%FY2024 · since FY2021: -126.8% → -805.9%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | -805.9% | -735.8 pp |
| FY2023 | -70.1% | -1.6 pp |
| FY2022 | -68.5% | +58.3 pp |
| FY2021 | -126.8% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice